Inhibrx provides updates on INBRX-106 and INBRX-109 expansion cohorts for oncology therapy. Dec. 16, 2025. (Tweet)Today, in San Diego, Inhibrx Biosciences, Inc. (Nasdaq: INBX), a company specializing in oncology therapeutics, provided an update on the INBRX-106 Phase 2/3 clinical trial. This trial aims to develop treatments for cancer.
